Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Atherosclerotic plaque

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    63 result(s) found for: Atherosclerotic plaque. Displaying page 1 of 4.
    1  2  3  4  Next»
    EudraCT Number: 2008-005288-33 Sponsor Protocol Number: EMI111784 Start Date*: 2008-12-18
    Sponsor Name:GlaxoSmithKline Research & Development, LtdD
    Full Title: Methodology Study to develop Sinerem enhanced 3T MR Imaging of Atherosclerotic Plaques within the Carotid Arteries, and to compare Sinerem MRI to contrast enhanced ultrasound
    Medical condition: Atherosclerotic plaque within the carotid artery.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2014-001666-10 Sponsor Protocol Number: 20140415 Start Date*: 2014-06-24
    Sponsor Name:Academic Medical Center Amsterdam
    Full Title: Local delivery of CER-001 in advanced plaques Proof-of-concept for apoA-1 as initiator of reverse cholesterol transport (LOCATION)
    Medical condition: Atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2005-004727-18 Sponsor Protocol Number: CORUNO/II/05.1 Start Date*: 2008-06-20
    Sponsor Name:THERABEL PHARMACEUTICAL Ltd
    Full Title: EFFECT OF MOLSIDOMINE 16 MG ADMINISTERED ONCE-DAILY AS A LONG-TERM ADD-ON TREATMENT, ON ATHEROSCLEROSIS PROGRESSION AND INFLAMMATORY BIOMARKERS IN PATIENTS HOSPITALIZED FOR ACUTE CORONARY SYNDROME.
    Medical condition: Randomized, double-blind, placebo-controlled, add-on study in two parallel groups. Patients admitted for Non ST Segment Elevation Acute Coronary Syndromes will undergo a coronary angiography accord...
    Disease: Version SOC Term Classification Code Term Level
    7.0 10011085 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2019-002452-16 Sponsor Protocol Number: PTO95105013 Start Date*: 2020-02-04
    Sponsor Name:UMC Utrecht
    Full Title: Inhibition of Mast cell Activation in AtheroScleroTic lesions using an Anti-IgE antibody approach (MAST-trial)
    Medical condition: Atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-000543-27 Sponsor Protocol Number: 19852012 Start Date*: 2012-04-23
    Sponsor Name:AMC
    Full Title: A Proof of Concept Study to Determine the Local Delivery and Efficacy of Intravenously Injected PEG-Liposomal Prednisolone Sodium Phosphate (Nanocort®) in Atherosclerotic Tissue in Subjects with Pe...
    Medical condition: Vessel wall inflammation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-001053-44 Sponsor Protocol Number: Carotis-Rivaroxaban_CEUS_001 Start Date*: 2020-09-30
    Sponsor Name:Rigshospitalet, Department of Vascular Surgery
    Full Title: Stabilization of vulnerable atherosclerotic carotid plaques by Rivaroxaban as evaluated by 3D contrast enhanced ultrasound (CEUS)
    Medical condition: Patients with - Stable peripheral artery disease and - Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004852 10075495 Internal carotid artery atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-005924-97 Sponsor Protocol Number: cro1120 Start Date*: 2008-10-23
    Sponsor Name:Imperial College
    Full Title: A 12 week observational study to evaluate the effects of the initiation of chemotherapy with anti-angiogenic activity on neovascularisation (as determined by contrast enhanced ultrasound, (CEUS)) w...
    Medical condition: Carotid atherosclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2022-003381-21 Sponsor Protocol Number: RAFAEL Start Date*: 2023-09-11
    Sponsor Name:Psyon, s.r.o.
    Full Title: Regression of atherosclerosis induced by life changing experience with psilocybin
    Medical condition: Ischemic Heart Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2017-004299-69 Sponsor Protocol Number: ARCHITECT Start Date*: 2018-04-25
    Sponsor Name:Fundación Hipercolesterolemia Familiar
    Full Title: Low interventional, open and multicentric clinical trial to evaluate the effect of alirocumab on volume, architecture and composition of atheroma plaque in patients with familial hypercholesterole...
    Medical condition: Heterozygous familial hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10057099 Heterozygous familial hypercholesterolaemia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005092-39 Sponsor Protocol Number: TA-8995-304 Start Date*: 2022-08-25
    Sponsor Name:NewAmsterdam Pharma BV
    Full Title: Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular...
    Medical condition: atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) IT (Trial now transitioned) SK (Trial now transitioned) NL (Trial now transitioned) HU (Trial now transitioned) BG (Trial now transitioned) DK (Trial now transitioned) CZ (Trial now transitioned) FI (Trial now transitioned) LV (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-005065-40 Sponsor Protocol Number: TA-8995-302 Start Date*: 2022-05-13
    Sponsor Name:NewAmsterdam Pharma B.V.
    Full Title: Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies (BROADWAY): A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participant...
    Medical condition: dyslipidemia heterozygous familial hypercholesterolemia (HeFH) atherosclerotic cardiovascular disease (ASCVD)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004848 10020049 High cholesterol LLT
    20.0 100000004850 10057079 Heterozygous familial hypercholesterolemia LLT
    26.0 100000004866 10051615 Atherosclerotic cardiovascular disease LLT
    20.0 100000004866 10076622 Atherosclerotic plaque LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) DK (Completed) CZ (Completed)
    Trial results: (No results available)
    EudraCT Number: 2023-000166-33 Sponsor Protocol Number: SLICK-001 Start Date*: 2023-04-12
    Sponsor Name:Semmelweis University
    Full Title: Implementation study of lipid management of high-risk cardiovascular patients- Semmelweis Lipid Center for high-risk patients
    Medical condition: primary hypercholesterolaemia (heterozygous familial and non-familial) or mixed dyslipidaemia in atherosclerotic cardiovascular disease
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004861 10020604 Hypercholesterolemia LLT
    20.0 100000004850 10054380 Familial hypercholesterolemia LLT
    20.0 100000004850 10077966 Primary hypercholesterolemia LLT
    21.0 100000004861 10058110 Dyslipidemia LLT
    20.1 100000004861 10079969 Atherogenic dyslipidemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2021-004601-47 Sponsor Protocol Number: CKJX839D12303 Start Date*: 2022-05-09
    Sponsor Name:NOVARTIS PHARMA AG
    Full Title: A multi-center, randomized, double-blind, placebo controlled, parallelgroup Phase IIIb study evaluating the effect of inclisiran on atherosclerotic plaque progression assessed by coronary computed ...
    Medical condition: Non-obstructive coronary artery disease
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10011078 Coronary artery disease PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) HU (Trial now transitioned) BE (Trial now transitioned) FR (Trial now transitioned) ES (Ongoing) IE (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2008-002169-30 Sponsor Protocol Number: GlaMet1 Start Date*: 2008-09-19
    Sponsor Name:Greater Glasgow Health Board, Research and Development Department [...]
    1. Greater Glasgow Health Board, Research and Development Department
    2. Senior Contracts Manager,Research and Enterprise,University of Glasgow
    Full Title: A randomised placebo-controlled trial of metformin on progression of carotid atherosclerosis in non-diabetic patients with cardiovascular disease treated with conventional risk reducing agents
    Medical condition: Participants must have definite coronary heart disease: either a previous myocardial infarction or positive findings on coronary angiogram. They can have normal glucose tolerance, impaired fasting ...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10051615 Atherosclerotic cardiovascular disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-005703-42 Sponsor Protocol Number: TMT106468 Start Date*: 2006-03-29
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A 12 week, randomised, double blind study evaluating the effects of low dose (10mg) and high dose (80mg) atorvastatin on macrophage activity and carotid plaque inflammation as determined by Ultra s...
    Medical condition: Atherosclerotic Carotid Disease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2006-001237-17 Sponsor Protocol Number: PETPLAQUE Start Date*: 2004-09-10
    Sponsor Name:Raitakari Olli
    Full Title: Imaging the vulnerable carotid artery atherosclerotic plaque
    Medical condition: carotid atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002483-31 Sponsor Protocol Number: UZBRU_VHH2_2 Start Date*: 2020-11-30
    Sponsor Name:UZ Brussel
    Full Title: Phase II study to evaluate the clinical potential of 68GaNOTA-Anti-MMR-VHH2 for in vivo imaging of MMR-expressing Macrophages by means of Positron Emission Tomography (PET) in oncological lesions, ...
    Medical condition: C1: malignancies of the head and neck. C2: malignancy with a solid component C3: carotid plaque, planned for (SOC) carotid endarterectomy. C4: biopsy-proven Hodgkin or non-Hodgkin lymphoma. C5: su...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005029-19 Sponsor Protocol Number: CV010031 Start Date*: 2020-06-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Global, Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of BMS-986177, an Oral Factor XIa Inhibitor, for the Prevention of New Ischemic Stroke or New Covert Brain Infarc...
    Medical condition: Ischemic Stroke or Transient Ischemic Attack (TIA)
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029205 - Nervous system disorders 10044390 Transient ischaemic attack PT
    22.1 10029205 - Nervous system disorders 10061256 Ischaemic stroke PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Completed) DE (Completed) ES (Ongoing) SE (Completed) HU (Completed) NO (Completed) FI (Completed) BE (Completed) GB (GB - no longer in EU/EEA) AT (Completed) DK (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2009-014618-80 Sponsor Protocol Number: CACZ885I2206 Start Date*: 2010-09-20
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi center, randomized, double blind, placebo-controlled, study of the safety, tolerability, and the effects on arterial structure and function of ACZ885 in patients with clinically evident ath...
    Medical condition: atherosclerosis type 2 diabetes mellitus (T2DM)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10027433 - Metabolism and nutrition disorders 10012594 Diabetes LLT
    14.1 10047065 - Vascular disorders 10003601 Atherosclerosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-017725-19 Sponsor Protocol Number: NC22703 Start Date*: Information not available in EudraCT
    Sponsor Name:F. Hoffmann-La Roche AG
    Full Title: A Phase IIIB multicenter, double-blind, randomized, placebocontrolled study, evaluating the effect of treatment with dalcetrapib 600 mg on Atherosclerotic Disease as measured by I. Coronary Intrava...
    Medical condition: A Study of the Effect of Dalcetrapib on Artherosclerotic Disease in Patients With Coronary Artery Disease.
    Disease: Version SOC Term Classification Code Term Level
    12.1 10011078 Coronary artery disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 17 16:04:35 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA